To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
Status:
Recruiting
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group,
Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P59
in Healthy Subjects.